R. Singh, K. Hristova, J. Fedacko, G. Elkilany, N. Verma
{"title":"New Clinical Trials With Evolocumab and Alirocumab on Cardiovascular Outcomes, in Patients With High Rsk of Acute Coronary Syndromes","authors":"R. Singh, K. Hristova, J. Fedacko, G. Elkilany, N. Verma","doi":"10.17554/j.issn.2309-6861.2015.02.93","DOIUrl":null,"url":null,"abstract":"Evolocumab, alirocumab and bococizumab are leading monoclonal antibodies that are called Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. These agents have been used in multicenter studies to demonstrate their efficacy and safety and effect on blood lipoproteins as well as on cardiovascular outcomes indicating significant beneficial effects without much adverse effects.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"1 1","pages":"422-424"},"PeriodicalIF":0.0000,"publicationDate":"2015-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical cardiology and cardiovascular therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17554/j.issn.2309-6861.2015.02.93","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Evolocumab, alirocumab and bococizumab are leading monoclonal antibodies that are called Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. These agents have been used in multicenter studies to demonstrate their efficacy and safety and effect on blood lipoproteins as well as on cardiovascular outcomes indicating significant beneficial effects without much adverse effects.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
